Prosecution Insights
Prosecution Insights
19 pending office actions • 8 clients • 17 examiners • 15 art units • 0 of 19 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 19 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 19 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §103 only | 10 (53%) |
| §102 only | 1 (5%) |
| §112 only | 4 (21%) |
| No statute on record | 3 (16%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KY, KEVIN | 3 | 76.6% | +25.6% |
| BUI, LUAN KIM | 1 | 69.0% | +28.3% |
| KANG, TAE-SIK | 1 | 58.0% | +27.2% |
| VANNI, GEORGE STEVEN | 1 | 66.8% | +24.3% |
| HIJAZ, OMAR F | 1 | 55.5% | +35.2% |
| KANAAN, TONY P | 1 | 29.3% | +28.9% |
| KNIGHT, TERESA E | 1 | 65.1% | +49.5% |
| CRAIG, KAILA ANGELIQUE | 1 | 32.8% | +26.7% |
| LOCKARD, JON MCCLELLAND | 1 | 74.5% | +27.0% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 63.8% | +59.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18374875 | METHOD FOR IDENTIFYING AND INITIATING REVERSIBLE SUBROGATION CLAIMS | KANAAN, TONY P | 14d |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | VANNI, GEORGE STEVEN | 84d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036815 | SECRETOME FRACTIONS AND USES THEREOF | KNIGHT, TERESA E | 58d overdue |
| 17702648 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | CUNNINGCHEN, KATHLEEN MARY | 35d overdue |
| 18382028 | ANCHORING PLATE | HIJAZ, OMAR F | 30d overdue |
| 18838315 | LIQUID CRYSTAL ELASTOMER WITH INTEGRATED SOFT THERMOELECTRICS FOR SHAPE MEMORY ACTUATION AND ENERGY HARVESTING | KANG, TAE-SIK | 9d overdue |
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | BUI, LUAN KIM | 13d |
| 18374875 | METHOD FOR IDENTIFYING AND INITIATING REVERSIBLE SUBROGATION CLAIMS | KANAAN, TONY P | 14d |
| 18146149 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | LOCKARD, JON MCCLELLAND | 14d |
| 19325482 | Semantically Interpreted Video Method, System, and Apparatus | KY, KEVIN | 29d |
| Client (Assignee) | Pending OAs |
|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | 7 |
| NOVEOME BIOTHERAPEUTICS, INC. | 4 |
| Revealit Corporation | 3 |
| Roesler IP GmbH | 1 |
| CARNEGIE MELLON UNIVERSITY | 1 |
| Signature Diagnostics Inc. | 1 |
| Spinnanker GmbH | 1 |
| Second Look, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 2671 | 3 |
| 1618 | 2 |
| 1647 | 2 |
| 3736 | 1 |
| 1728 | 1 |
| 1686 | 1 |
| 3635 | 1 |
| 3696 | 1 |
| 1634 | 1 |
| 1646 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19325482 | Semantically Interpreted Video Method, System, and Apparatus | Revealit Corporation | KY, KEVIN | 2671 | §112 | Final Rejection | 29d | Pending | Sep 10, 2025 |
| 19325478 | SEMANTICALLY GENERATED VIDEO METHOD AND SYSTEM | Revealit Corporation | KY, KEVIN | 2671 | §112 | Final Rejection | 30d | Pending | Sep 10, 2025 |
| 19224794 | NEURAL NETWORK TRAINING FOR VIDEO GENERATION | Revealit Corporation | KY, KEVIN | 2671 | §112 | Final Rejection | 29d | Pending | May 31, 2025 |
| 18883446 | RESILIENT EXPANDABLE STERILIZABLE PACKAGING FOR INDIVIDUAL ITEMS | Roesler Ip GmbH | BUI, LUAN KIM | 3736 | §103 | Non-Final OA | 13d | Pending | Sep 12, 2024 |
| 18838315 | LIQUID CRYSTAL ELASTOMER WITH INTEGRATED SOFT THERMOELECTRICS FOR SHAPE MEMORY ACTUATION AND ENERGY HARVESTING | Carnegie Mellon University | KANG, TAE-SIK | 1728 | §103 | Non-Final OA | 9d overdue | Pending | Aug 14, 2024 |
| 18514319 | RELATIONAL BIOMARKERS THAT DISTINGUISH DISEASES AND DISORDERS FROM CONTROLS AND USES THEREOF TO PREDICT PATHOPHYSIOLOGICAL OUTCOMES | Signature Diagnostics Inc. | VANNI, GEORGE STEVEN | 1686 | §101 | Non-Final OA | 84d | Pending | Nov 20, 2023 |
| 18382028 | ANCHORING PLATE | Spinnanker GmbH | HIJAZ, OMAR F | 3635 | §112 | Final Rejection | 30d overdue | Pending | Oct 19, 2023 |
| 18374875 | METHOD FOR IDENTIFYING AND INITIATING REVERSIBLE SUBROGATION CLAIMS | Second Look, Inc. | KANAAN, TONY P | 3696 | §103 | Non-Final OA | 14d | Pending | Sep 29, 2023 |
| 18036815 | SECRETOME FRACTIONS AND USES THEREOF | Noveome Biotherapeutics, Inc. | KNIGHT, TERESA E | 1634 | §103 | Non-Final OA | 58d overdue | Pending | May 12, 2023 |
| 18025849 | TROPHOBLAST GLYCOPROTEIN RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Non-Final OA | 39d | Pending | Mar 10, 2023 |
| 18146149 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. | LOCKARD, JON MCCLELLAND | 1647 | Other | Non-Final OA | 14d | Pending | Dec 23, 2022 |
| 17702648 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Actinium Pharmaceuticals, Inc. | CUNNINGCHEN, KATHLEEN MARY | 1646 | Other | Non-Final OA | 35d overdue | Pending | Mar 23, 2022 |
| 17494690 | MODULATING ISCHEMIC INJURY | Noveome Biotherapeutics, Inc. | CLARKE, TRENT R | 1651 | §102 | Final Rejection | 141d overdue | Pending | Oct 05, 2021 |
| 17197580 | Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 Syndrome | Noveome Biotherapeutics, Inc. | FORD, VANESSA L | 1674 | §103 | Final Rejection | 6d | Pending | Mar 10, 2021 |
| 16954105 | COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY | Actinium Pharmaceuticals, Inc. | WELLS, LAUREN QUINLAN | 1622 | §103 | Non-Final OA | 30d overdue | Pending | Jun 15, 2020 |
| 16755590 | ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES | Actinium Pharmaceuticals, Inc. | JOHANSEN, PETER N. | 1644 | §103 | Final Rejection | 30d overdue | Pending | Apr 12, 2020 |
| 16754400 | METHODS FOR CANCER TREATMENT USING A RADIOLABELED ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELL THERAPIES | Actinium Pharmaceuticals, Inc. | BUTTICE, AUDREY L | 1647 | §103 | Final Rejection | 33d | Pending | Apr 08, 2020 |
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | Actinium Pharmaceuticals, Inc. | SAMALA, JAGADISHWAR RAO | 1618 | §103 | Non-Final OA | 58d overdue | Pending | Dec 31, 2019 |
| 16690197 | Novel methods for delivering therapeutics agents to the eye via the nasal passages | Noveome Biotherapeutics, Inc. | MOSS, NATALIE M | 1653 | Other | Non-Final OA | 6d | Pending | Nov 21, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial